His work in Optics is not limited to one particular discipline; it also encompasses Detector. As part of his studies on Detector, he often connects relevant areas like Optics. Quantum mechanics and Dispersion (optics) are frequently intertwined in his study. Dispersion (optics) is closely attributed to Quantum mechanics in his study. His multidisciplinary approach integrates Large Hadron Collider and Particle physics in his work. He integrates Particle physics and Nuclear physics in his studies. Many of his studies on Nuclear physics apply to Large Hadron Collider as well. He performs multidisciplinary study in the fields of Position (finance) and Finance via his papers. Volkmar Müller combines Finance and Position (finance) in his research.
Volkmar Müller's looking at Metastasis as part of his Circulating tumor cell and Primary tumor and Metastasis study. His work on Proportional hazards model expands to the thematically related Internal medicine. His research is interdisciplinary, bridging the disciplines of Internal medicine and Proportional hazards model. Volkmar Müller carries out multidisciplinary research, doing studies in Cancer and Chemotherapy. His work blends Chemotherapy and Metastasis studies together. His study deals with a combination of Breast cancer and Metastatic breast cancer. Volkmar Müller combines Oncology and Pathology in his research. In his works, Volkmar Müller conducts interdisciplinary research on Pathology and Oncology. He performs integrative study on Quantum mechanics and Optics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tumour exosome integrins determine organotropic metastasis
Ayuko Hoshino;Bruno Costa-Silva;Tang-Long Shen;Goncalo Rodrigues.
Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System
Sabine Riethdorf;Herbert Fritsche;Volkmar Müller;Thomas Rau.
Clinical Cancer Research (2007)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits;Margaretha Rudas;Raimund Jakesz;Peter Dubsky.
Clinical Cancer Research (2011)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata.
The New England Journal of Medicine (2020)
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch;Peter A. Fasching;Gottfried E. Konecny;Stephan Hasmüller.
Journal of Clinical Oncology (2011)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf;Volkmar Müller;Liling Zhang;Thomas Rau.
Clinical Cancer Research (2010)
Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity
Volkmar Müller;Nicole Stahmann;Sabine Riethdorf;Thomas Rau.
Clinical Cancer Research (2005)
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
Carina Roth;Brigitte Rack;Volkmar Müller;Wolfgang Janni.
Breast Cancer Research (2010)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Tanja Fehm;Volkmar Müller;Bahriye Aktas;Wolfgang Janni.
Breast Cancer Research and Treatment (2010)
The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.
Monica M. Montano;Volkmar Müller;Angela Trobaugh;Benita S Katzenellenbogen.
Molecular Endocrinology (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: